[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494764":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":30,"responsibleParty":298,"collaborators":22,"id":300,"slug":22,"hasResults":301,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":301,"sex":307,"minAge":308,"maxAge":22,"enrollmentInfo":309,"targetDuration":22,"studyType":312,"phases":313,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":33,"whyStopped":22,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":340},{"fullName":5,"class":6},"Caribou Biosciences, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CB-011","EXPERIMENTAL","* Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design.\n* Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE\u002FMTD and\u002For RP2D determined in Plan A",[13],"Biological: CB-011",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion",[9],[20,21],"Cyclophosphamide","Fludarabine",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Caribou Biosciences","CONTACT","510-982-6030","3","clinicaltrials@cariboubio.com",[31,49,71,87,104,121,136,148,164,180,196,211,231,247,264,281],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35294","United States",{"type":39,"coordinates":40},"Point",[41,42],-86.80249,33.52066,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":47,"phoneExt":22,"email":48},"Luciano Costa, MD","205-975-3371","ljcosta@uabmc.edu",{"facility":50,"status":33,"city":51,"state":52,"zip":53,"country":37,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"CU Anschutz Medical Campus, Anshutz Cancer Pavillion","Aurora","Colorado","80045",{"type":39,"coordinates":55},[56,57],-104.83192,39.72943,{"lat":57,"lon":56},[60,64,68],{"name":61,"role":26,"phone":62,"phoneExt":22,"email":63},"Rona Wang","303-724-2703","deng.wang@cuanschutz.edu",{"name":65,"role":26,"phone":66,"phoneExt":22,"email":67},"Natalie Pfenning","303-724-9562","natalie.pfenning@cuanschutz.edu",{"name":69,"role":70,"phone":22,"phoneExt":22,"email":22},"Daniel Sherbenou, MD, PhD","PRINCIPAL_INVESTIGATOR",{"facility":72,"status":33,"city":73,"state":74,"zip":75,"country":37,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics","Miami","Florida","33136",{"type":39,"coordinates":77},[78,79],-80.19366,25.77427,{"lat":79,"lon":78},[82,86],{"name":83,"role":26,"phone":84,"phoneExt":22,"email":85},"Jay Spiegel, MD","305-243-0372","Spiegelj@med.miami.edu",{"name":83,"role":70,"phone":22,"phoneExt":22,"email":22},{"facility":88,"status":33,"city":89,"state":90,"zip":91,"country":37,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"University of Kentucky\u002F Markey Cancer Center","Lexington","Kentucky","40536",{"type":39,"coordinates":93},[94,95],-84.47772,37.98869,{"lat":95,"lon":94},[98,102],{"name":99,"role":26,"phone":100,"phoneExt":22,"email":101},"Ashley Walton-Robbins","589-218-1758","Ashley.robbins@uky.edu",{"name":103,"role":70,"phone":22,"phoneExt":22,"email":22},"Gregory Monohan, MD",{"facility":105,"status":33,"city":106,"state":107,"zip":108,"country":37,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Hackensack Meridian John Theurer Cancer Center","Hackensack","New Jersey","07601",{"type":39,"coordinates":110},[111,112],-74.04347,40.88593,{"lat":112,"lon":111},[115,119],{"name":116,"role":26,"phone":117,"phoneExt":22,"email":118},"Oncology Clinical Research Referral Office","551-996-1777","oncologyresearchreferral@hmhn.org",{"name":120,"role":70,"phone":22,"phoneExt":22,"email":22},"David Siegal, MD",{"facility":122,"status":33,"city":123,"state":123,"zip":124,"country":37,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Icahn School of Medicine at Mount Sinai","New York","10029",{"type":39,"coordinates":126},[127,128],-74.00597,40.71427,{"lat":128,"lon":127},[131,135],{"name":132,"role":26,"phone":133,"phoneExt":22,"email":134},"Adriana Rossi, MD","917-828-3905","adriana.rossi@mssm.edu",{"name":132,"role":70,"phone":22,"phoneExt":22,"email":22},{"facility":137,"status":33,"city":123,"state":123,"zip":138,"country":37,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"Memorial Sloan Kettering Cancer Center","10065",{"type":39,"coordinates":140},[127,128],{"lat":128,"lon":127},[143,147],{"name":144,"role":26,"phone":145,"phoneExt":22,"email":146},"Sham Mailankody, MBBS","646-608-2091","cart@mskcc.org",{"name":144,"role":70,"phone":22,"phoneExt":22,"email":22},{"facility":149,"status":33,"city":150,"state":151,"zip":152,"country":37,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":39,"coordinates":154},[155,156],-80.84313,35.22709,{"lat":156,"lon":155},[159,162],{"name":160,"role":26,"phone":22,"phoneExt":22,"email":161},"Kelly Bumgarner","Kelly.Bumgarner@atriumhealth.org",{"name":163,"role":70,"phone":22,"phoneExt":22,"email":22},"Manisha Bhutani, MD",{"facility":165,"status":33,"city":166,"state":151,"zip":167,"country":37,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Duke University Health System (DUHS)","Durham","27705",{"type":39,"coordinates":169},[170,171],-78.89862,35.99403,{"lat":171,"lon":170},[174,178],{"name":175,"role":26,"phone":176,"phoneExt":22,"email":177},"Matthew Fisher","919-668-1028","Matthew.Fister@Duke.edu",{"name":179,"role":70,"phone":22,"phoneExt":22,"email":22},"Cristina Gasparetto, MD",{"facility":181,"status":33,"city":182,"state":183,"zip":184,"country":37,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Oncology Hematology Care, Inc","Cincinnati","Ohio","45236",{"type":39,"coordinates":186},[187,188],-84.51439,39.12711,{"lat":188,"lon":187},[191,194],{"name":192,"role":26,"phone":22,"phoneExt":22,"email":193},"Doug Hart","douglas.hart@usoncology.com",{"name":195,"role":70,"phone":22,"phoneExt":22,"email":22},"James Essell, MD",{"facility":197,"status":33,"city":198,"state":183,"zip":199,"country":37,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Cleveland Clinic","Cleveland","44195",{"type":39,"coordinates":201},[202,203],-81.69541,41.4995,{"lat":203,"lon":202},[206,209],{"name":22,"role":26,"phone":207,"phoneExt":22,"email":208},"216-444-7923","Canceranswer@ccf.org",{"name":210,"role":70,"phone":22,"phoneExt":22,"email":22},"Faiz Anwer, MD",{"facility":212,"status":33,"city":213,"state":214,"zip":215,"country":37,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"Tennessee Oncology","Nashville","Tennessee","37203",{"type":39,"coordinates":217},[218,219],-86.78444,36.16589,{"lat":219,"lon":218},[222,226,230],{"name":223,"role":26,"phone":224,"phoneExt":22,"email":225},"Jesus Berdeja, MD","844-482-4812","jberdeja@tnonc.com",{"name":227,"role":26,"phone":228,"phoneExt":22,"email":229},"Taylor Peach","629-292-7183","tpeach@tnonc.com",{"name":223,"role":70,"phone":22,"phoneExt":22,"email":22},{"facility":232,"status":33,"city":233,"state":234,"zip":235,"country":37,"cosmosGeoPoint":236,"geoPoint":240,"contacts":241},"University of Texas Southwestern Medical Center","Dallas","Texas","75390",{"type":39,"coordinates":237},[238,239],-96.80667,32.78306,{"lat":239,"lon":238},[242,245],{"name":243,"role":26,"phone":22,"phoneExt":22,"email":244},"Marcella Aguilar","Marcella.Aguilar@utsouthwestern.edu",{"name":246,"role":70,"phone":22,"phoneExt":22,"email":22},"Larry Anderson, MD",{"facility":248,"status":33,"city":249,"state":250,"zip":251,"country":37,"cosmosGeoPoint":252,"geoPoint":256,"contacts":257},"Huntsman Cancer Institute, University of Utah","Salt Lake City","Utah","84112",{"type":39,"coordinates":253},[254,255],-111.89105,40.76078,{"lat":255,"lon":254},[258,262],{"name":259,"role":26,"phone":260,"phoneExt":22,"email":261},"Collind Boyington","801-587-4779","collind.boyington@HCI.UTAH.EDU",{"name":263,"role":70,"phone":22,"phoneExt":22,"email":22},"Douglas Sborov, MD",{"facility":265,"status":33,"city":266,"state":267,"zip":268,"country":37,"cosmosGeoPoint":269,"geoPoint":273,"contacts":274},"Virginia Commonwealth University","Richmond","Virginia","23235",{"type":39,"coordinates":270},[271,272],-77.46026,37.55376,{"lat":272,"lon":271},[275,279],{"name":276,"role":26,"phone":277,"phoneExt":22,"email":278},"Johanna Biamonte","804-628-1896","jbiamonte@vcu.edu",{"name":280,"role":70,"phone":22,"phoneExt":22,"email":22},"William Clark, MD",{"facility":282,"status":33,"city":283,"state":284,"zip":285,"country":37,"cosmosGeoPoint":286,"geoPoint":290,"contacts":291},"Froedtert and the Medical College of Wisconsin","Milwaukee","Wisconsin","53226",{"type":39,"coordinates":287},[288,289],-87.90647,43.0389,{"lat":289,"lon":288},[292,296],{"name":293,"role":26,"phone":294,"phoneExt":22,"email":295},"Danielle King","414-805-9334","daking@mcw.edu",{"name":297,"role":70,"phone":22,"phoneExt":22,"email":22},"Binod Dhakal, MD",{"type":299,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100494764",false,"NCT05722418","CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma (CaMMouflage Trial)","CaMMouflage","Inclusion Criteria:\n\n1. Documented diagnosis of relapsed\u002Frefractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)\n2. Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody as part of a prior line of therapy, either in monotherapy or in combination.\n3. Eastern Cooperative Oncology Group performance status grade of 0 or 1.\n4. Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.\n\nExclusion Criteria:\n\n1. Prior treatment with CAR-T cell therapy directed at any target.\n2. Autologous stem cell transplant within the last 6 weeks before lymphodepletion.\n3. Allogeneic stem cell transplant within 6 months before lymphodepletion.\n4. Known active or prior history of CNS involvement.\n5. Stroke or seizure within 6 months of signing ICF.\n6. Seropositive for or history of human immunodeficiency virus.\n7. Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion.\n8. Hepatitis B infection.\n9. Hepatitis C infection.\n10. Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or its excipients.","ALL","18 Years",{"count":310,"type":311},50,"ESTIMATED","INTERVENTIONAL",[314],"PHASE1","This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).",[317],"Relapsed\u002FRefractory Multiple Myeloma",[305,319,320,321,322,323,324,325,326,9,327,328,329,330],"Allogeneic","Multiple Myeloma","Relapse Refractory Multiple Myeloma","CAR-T Cells","BCMA","Cell Therapy","Cellular Immuno-therapy","CB11A","CB-011A","CAR-T","Anti BCMA","ALLO CAR T","2025-09-23",{"date":333,"type":334},"2025-09-25","ACTUAL",{"date":336,"type":334},"2023-02-06",{"date":338,"type":311},"2027-12",{"name":5,"class":6},16]